Association of EBV and HPV co-infection with the development of cervical cancer in ethnic Uyghur women

Objective: Study on the role of Epstein-Barr virus (EBV) and human papillomavirus (HPV) infection in the development of cervical cancer. Materials and Methods: We collected 178 cases of cervical tissue specimens of Uyghur women with cervicitis, cervical intraepithelial neoplasia (CIN I, CIN II-III), and cervical squamous cell carcinoma (CSCC). EBV- and HPV-DNA were detected by PCR of tissue DNA. EBV protein expression was checked by immunohistochemistry. Results: HPV-DNA was detectable in 2.5, 12.5, 68.0, and 96.4% of cases of cervicitis, CIN I, CIN II- III, and cervical cancer, respectively. For EBV-DNA, these numbers were 0, 3.1, 28.0, and 69.6%. There was a significant difference between the groups of cervicitis, CIN II-III, and cancer with respect to both HPV and EBV positivity rates (p < 0.05). Further analysis indicated that cervical lesion pathogenesis was not only accompanied by a gradually increasing rate of HPV or EBV-DNA alone, but also by an increasing rate of HPV-EBV dual infection (r = 0.46; p < 0.01). EBV protein expression was positive in 89.7% of EBV-DNA positive cases (34/39) and 6% of EBV-DNA negative cases (1/17). Conclusion: Cervical cancer development and progression may be closely associated with the dual-infection by HPV and EBV.

[1] Franco E.L., Schlecht N.F., Saslow D.: “The epidemiology of cervi-cal cancer”. Cancer J., 2003, 9, 348.

[2] Parkin D.M., Bray F., Ferlay J., Pisani P.: “Estimating the world cancer burden: Globocan 2000”. Int. J. Cancer, 2001, 94, 153.

[3] Parkin D.M.: “Global cancer statistics in the year 2000”. Lancet Oncol., 2001, 2, 533.

[4] Suzuke L., Peng Y., Zhou K.: “The analysis of pathogenetic tendency of cervical cancer in various ethnic groups in Xinjiang”. Journal of Xinjiang Medical University, 2006, 29, 569.

[5] Guzalinuer A., Peng Z., Guo Y.: “HPV and its subtypes in the Han nationality in Sichuan and the northwestern region of Xinjiang Uygur southern region of cervical tissue of women differentially expressed”. Chinese Journal of Microbiology and Immunology, 2004, 24, 402-406.

[6] Missaoui N., Hmissa S., Trabelsi A., Frappart L., Mokni M., Korbi S.: “Cervix cancer in Tunisia: Clinical and pathological study”. Asian Pac. J. Cancer Prev., 2010, 11, 235.

[7] zur Hausen H.: “Papillomaviruses causing cancer: Evasion from hostcell control in early events in carcinogenesis”. J. Natl. Cancer Inst., 2000, 92, 690.

[8] zur Hausen H., Gissmann L., Schlehofer J.R.: “Viruses in the etiology of human genital cancer”. Prog. Med. Virol., 1984, 30, 170.

[9] Abida Abudukadeer, Yan Ding, Mayinuer Niyazi, Abulizi Abudula. Distribution of HPV genotypes in uterine cervical lesions among the Uyghur women in Xinjiang province of China”. Eur. J. Gynaecol. Oncol., 2010, 31, 315.

[10] Tseng C.J., Pao C.C., Tseng L.H., Chang C.T., Lai C.H., Soong Y.K., et al.:”Lymphoepithelial carcinoma like carcinoma of the uterine cervix: association with Epstein-Barr virus and human papillo-mavirus”. Cancer, 1997, 80, 91.

[11] Thompson S., Messick T., Schultz D.C., Reichman M., Lieberman P. M.: “Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1”. J. Biomol. Screen., 2010, 15, 1107.

[12] Kahla S., Oueslati S., Achour M., Kochbati L., Chanoufi M.B., Maalej M., Oueslati R.: “Correlation between ebv co-infection and HPV16 genome integrity in Tunisian cervical cancer patients”. Braz. J. Microbiol., 2012, 43, 744.

[13] Landers R.J., O’Leary J.J., Crowley M., Healy I., Annis P., Burke L., et al.: “Epstein-Barr virus in normal, pre-malignant, and malig-nant lesions of the uterine cervix”. J. Clin. Pathol., 1993, 46, 931.

[14] Sasagawa T., Shimakage M., Nakamura M., Sakaike J., Ishikawa H., Aki I.M.: “Epstein-Barr virus (EBV) genes expression in cervical intraepithelial neoplasia and invasive cervical cancer: a comparative study with human papillomavirus (HPV) infection”. Hum. Pathol., 2000, 31, 318.

[15] Noel J.C., Lespagnard L., Fayt I., Verhest A., Dargent J.L.: “Evidence of human papillomavirus infection but lack of Epstein-Barr virus in lymphoepitheliomalike carcinoma of uterine cervix: report of two cases and review of the literature”. Hum. Pathol., 2001, 32, 135.

[16] Bais A.G.T., Kooi S.T., Teune T.M., Patricia C., Ewing P.C., Ansink A. C.: “Lymphoepithelioma-like carcinoma of the uterine cervix: absence of Epstein -Barr virus, but presence of a multiple human pa-pillomavirus infection”. Gynecol. Oncol., 2005, 97, 716.

[17] Weinberg E., Hoisington S., Eastman A.Y., Rice D.K., Malfetano J., Ross J.S.: “Uterine cervical lymphoepithelial-like carcinoma: absence of Epstein-Barr virus genomes”. Am. J. Clin. Pathol., 1993, 99, 195.

[18] De Oliveira D.E., Monteiro F.T.A., De Melo A.W., Moreira AR.M., Alvarenga M., Bacchi C.E.: “Lack of Epstein-Barr virus infection in cervical carcinomas”. Arch. Pathol. Lab. Med., 1999, 123, 1098.

[19] Pisani P., Parkin D.M., Munoz N., Ferlay J.: “Cancer and infection: estimates of the attributable fraction in 1990”. Cancer Epidemiol. Biomarkers Prev., 1997, 6, 387.

[20] Parkin D.M.: “The global health burden of infection-associated can-cers in the year 2002”. Int. J. Cancer, 2006, 118, 3030.

[21] World Health Organization: “IARC monographs on the evaluation of carcinogenic risks to humans. Volume 64: Human papillomaviruses”. Lyon: IARC, 1995. Available at: http://monographs.iarc.fr/ENG/Monographs/vol64/mono64-1.pdf

[22] zur Hausen H: “Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis”. J. Natl. Cancer Inst., 2000, 92, 690.

[23] Missaoui N., Hmissa S., Trabelsi A., Frappart L., Mokni M., Korbi S.: “Cervix cancer in Tunisia: clinical and pathological study”. Asian Pac. J. Cancer Prev., 2010, 11, 235.

[24] Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., Clifford G.M.: “Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis up-date”. Int. J. Cancer, 2007, 121, 621.

[25] Smith J.S., Herrero R., Bosetti C., Munoz N., Bosch F.X., Eluf-Neto J., et al.: “Herpes simplex virus-2 as a human papi llomavirus co-factor in the etiology of invas ive cervic al cancer”. J. Natl. Cancer Inst., 2002, 94, 1604.

[26] Bajaj B.G., Murakami M., Robertson E.S.: “Molecular biology of EBV in relationship to AIDS-associated oncogenesis”. Cancer Treat. Res., 2007, 133, 141.

[27] Javier R.T., Butel J.S.: “The history of tumor virology”. Cancer Res., 2008, 68, 7693.

[28] Parkin D.M.: “The global health burden of infection-associated cancers in the year 2002”. Int. J. Cancer, 2006, 118, 3030.

[29] Lattario F., Furtado Y.L., Silveira F.A., do Val I.C., Almeida G., da Costa Carvalho Mda G.: “Evaluation of DAPK gene methylation and HPV and EBV infection in cervical cells from patients with norm al cytology and colposcopy”. Arch. Gynecol. Obstet., 2008, 277, 505.

[30] Silver M.I., Paul P., Sowjanya P., Ramakrishna G., Vedantham H., Kalpana B., et al.: “Shedding of Epstei n-Barr virus and cy-tomegalovirus from the genital tract of women in a periurban commu-nity in Andhra Pradesh, India”. J. Clin. Microbiol., 2011, 49, 2435.

[31] Szostek S., Zawilinska B., Klimek M., Kopec J., Kosz-Vnenchak M.: “Is the presence of herpesviruses in cervical secretions a prog-nostic factor for cervical pathology in HPV-positive women?” Przegl. Epidemiol., 2009, 63, 97.

[32] Voog E.: “Genital viral infections. Studies on human papillomavirus and Epstein-Barr virus”. Acta Derm. Venereol. Suppl. (Stockh), 1996, 198, 1.

[33] Szkaradkiewicz, A., Wal M., Kuch A., Pieta P.”: Human papillo-mavirus (HPV) and Epstein-Barr virus (EBV) cervical infections in women with normal and abnormal cytology”. Pol. J. Microbiol., 2004, 53, 95.

[34] Khenchouche A., Sadouki N., Boudriche A., Houali K., Graba A., Ooka T., Bouguermouh A.: “Human papillomavirus and Epstein-Barr virus co-infection in cervical carcinoma in Algerian women”. Virol. J., 2013, 10, 340.

[35] Shimabuku T., Tamanaha A., Kitamura B., Tanabe Y., Tawata N., Ike-hara F., et al.: “Dual expression of Epstein-Barr virus, latent mem-brane protein-1 and human papillomavirus-16 E6 transform primary mouse embryonic fibroblasts through NF-κB signaling”. Int. J. Clin. Exp. Pathol., 2014, 7, 1920.